

*Biopharmaceutical Contract Manufacturing:
Best Practices Pricing Study 2016*

Presented by

HighTech Business Decisions

3150 Almaden Expressway, Suite 222 San Jose, California 95118

Tel: (408) 978-1035 Fax: (408) 978-8925

www.HighTechDecisions.com

August 2016

Biopharmaceutical Contract Manufacturing: Best Practices Pricing Study 2016

TABLE OF CONTENTS

Chapter 1:	EXECUTIVE SUMMARY	
	1.1 Introduction	1-1
	1.2 Participants' Locations	1-2
	1.3 Industry Pricing Trends	1-3
	<i>1.3.1 Recent Industry Pricing Changes</i>	1-3
	<i>1.3.2 Changes in CMO Pricing in Next Two Years</i>	1-4
	1.4 Outsourcing Strategies and Contractor Selection	1-6
	<i>1.4.1 Users' Outsourcing Strategies</i>	1-6
	<i>1.4.2 Importance of Price in Decision-Making Process</i>	1-7
	<i>1.4.3 Technical Support Expected from CMO</i>	1-9
	<i>1.4.4 Use of China CMO for Chinese Market</i>	1-12
	1.5 Contractors' Business Strategies and Customer Types	1-13
	<i>1.5.1 Contractors' Client Segments</i>	1-13
	<i>1.5.2 Importance of Price in Clients' Decision-Making Process</i>	1-15
	<i>1.5.3 Provisions for Inflation in Contracts</i>	1-16
	<i>1.5.4 CMOs' Management of Development Risk</i>	1-18
	1.6 Contract Agreement: Expectations and Preferences	1-19
	<i>1.6.1 Preferred Pricing Models</i>	1-19
	<i>1.6.2 Premium Paid for Earliest Capacity Availability</i>	1-21
	<i>1.6.3 Typical Pricing Model for Development Services</i>	1-26
	1.7 Prices Paid and Prices Charged	1-27
	<i>1.7.1 Contractors' Pricing Models</i>	1-27
	<i>1.7.2 Pricing: Per-Batch, Per-Week, and Per-Gram</i>	1-30
	1.8 Improving Contract Agreements and Solving Problems	1-36
	<i>1.8.1 Users' Perspective: Negotiation Challenges</i>	1-36
	<i>1.8.2 Contractors' Perspective: Negotiation Challenges</i>	1-38
	<i>1.8.3 Contractors' Cancellation Fees for GMP Runs</i>	1-39
	<i>1.8.4 Users' Tolerance of CMO Rescheduling</i>	1-40
	<i>1.8.5 Final Observations</i>	1-42
Chapter 2:	METHODOLOGY, DEFINITIONS AND ACRONYMS	
	2.1 Research Objectives	2-1
	2.2 Research Methodology	2-2
	2.3 Definition of Biopharmaceutical Manufacturing	2-3
	2.4 Box-and-Whiskers Plot Definition	2-3
	2.5 Acronyms	2-4

Biopharmaceutical Contract Manufacturing: Best Practices Pricing Study 2016

TABLE OF CONTENTS (continued)

Chapter 3:	INDUSTRY PRICING TRENDS	
3.1	Introduction	3-1
3.1.1	<i>Participants' Locations and Job Titles</i>	3-1
3.1.2	<i>Approved Biopharmaceutical Products on Market</i>	3-3
3.1.3	<i>Number of Biopharmaceuticals in Clinical Trials</i>	3-4
3.1.4	<i>Product Produced in CMO Facility Licensed for Commercial Production</i>	3-6
3.2	Industry Pricing Trends	3-7
3.2.1	<i>Recent Industry Price Changes</i>	3-7
3.2.2	<i>Changes in CMO Pricing in the Next Two Years</i>	3-9
3.2.3	<i>Services Where Prices Have Changed the Most</i>	3-14
3.2.4	<i>Key Factors Affecting Manufacturing Costs</i>	3-17
3.3	Profit Margins	3-20
3.3.1	<i>Contractors' Target Gross Profit Margins</i>	3-20
<hr/>		
Chapter 4:	OUTSOURCING STRATEGIES/CONTRACTOR SELECTION	
4.1	Outsourcing Strategies	4-1
4.1.1	<i>Manufacturing Budgets: In-House versus Outsourced</i>	4-1
4.1.2	<i>Outsourcing Budgets: Process Development versus Manufacturing</i>	4-4
4.1.3	<i>Users' Outsourcing Strategies</i>	4-7
4.1.4	<i>Users' Future Changes to Outsourcing Strategy</i>	4-11
4.2	Contractor Relationships	4-15
4.2.1	<i>Users' Current Contractors</i>	4-15
4.2.2	<i>Plans for New or Different Contractors</i>	4-16
4.3	Contractor Selection	4-21
4.3.1	<i>Initial Contact with Contractors</i>	4-21
4.3.2	<i>Number of CMOs Contacted for Proposals for Project</i>	4-25
4.3.3	<i>Decision Maker for CMO Selection</i>	4-27
4.3.4	<i>Importance of Price in Decision-Making Process</i>	4-33
4.3.5	<i>Outsourcing of Mammalian Cell-Line Development</i>	4-38
4.3.6	<i>Technical Support Expected from CMO</i>	4-41
4.3.7	<i>Co-Work Opportunities with CMO</i>	4-48
4.3.8	<i>Consideration of Low Base Price with Bonuses Tied to Targets</i>	4-52
4.4	Contractor Location	4-57
4.4.1	<i>Geographic Location Impact on CMO Selection</i>	4-57
4.4.2	<i>Consideration of Asia-Based CMO</i>	4-61
4.4.3	<i>Use of China CMO for Chinese Market</i>	4-66

Biopharmaceutical Contract Manufacturing: Best Practices Pricing Study 2016

TABLE OF CONTENTS (continued)

Chapter 4:	4.5 Technology and Service Trends	4-71
	4.5.1 <i>Use of Proprietary Expression Systems</i>	4-71
	4.5.2 <i>Preferred Payment Model for Proprietary Expression Systems</i>	4-77
	4.5.3 <i>Inclusion of Engineering Runs in GMP Production Price</i>	4-80
	4.5.4 <i>Changes in Product Portfolio and New Technologies Needed</i>	4-81

Chapter 5: CONTRACTORS' BUSINESS STRATEGIES/CUSTOMER TYPES

5.1 Business Strategies	5-1
5.1.1 <i>CMO Focus or Business Strategy</i>	5-1
5.1.2 <i>Importance of Price in Clients' Decision-Making Process</i>	5-4
5.1.3 <i>Provisions for Inflation in Contracts</i>	5-9
5.1.4 <i>CMOs' Management of Development Risk</i>	5-11
5.2 Customer Base	5-15
5.2.1 <i>Fee-for-Service versus Partnership Contracts</i>	5-15
5.2.2 <i>Domestic versus International Clients</i>	5-16
5.2.3 <i>Contractors' Client Segments</i>	5-17
5.3 Technology and Service Trends	5-19
5.3.1 <i>Inclusion of Engineering Runs in GMP Production</i>	5-19
5.3.2 <i>Number of Runs in a Campaign</i>	5-21
5.3.3 <i>Provisions for Raw and Consumable Materials</i>	5-24
5.3.4 <i>Material Pass-Through Costs</i>	5-26
5.3.5 <i>Charging for Product Support/Project Management</i>	5-29
5.3.6 <i>Electronic Documentation</i>	5-31

Chapter 6: CONTRACT AGREEMENT: EXPECTATIONS/PREFERENCES

6.1 Users' Expectations of Pricing Models	6-1
6.1.1 <i>Expectations of Core Charges: Users versus Contractors</i>	6-1
6.1.2 <i>Preferred Pricing Models</i>	6-3
6.1.3 <i>Services Users are Willing to Pay a Premium for Speed</i>	6-5
6.1.4 <i>Mammalian Cell-Line Development Pricing and Time Expectation</i>	6-11
6.1.5 <i>Markups of CMO Purchased Materials</i>	6-13
6.1.6 <i>Users' Management of Development Risk</i>	6-17

Biopharmaceutical Contract Manufacturing: Best Practices Pricing Study 2016

TABLE OF CONTENTS (continued)

Chapter 6:	6.2 Contractors' Pricing Practices and Preferences	6-25
	6.2.1 <i>Services Clients Willing to Pay Premium for Speed</i>	6-25
	6.2.2 <i>Typical Pricing Model for Development Services</i>	6-29
	6.2.3 <i>Charging for Pre-Production Services</i>	6-32
	6.2.4 <i>Typical Charge for IND Submission Services</i>	6-33
	6.2.5 <i>Long-Term Supply Agreement with Clients</i>	6-36
	6.2.6 <i>Price Reduction Provisions from Process Improvements</i>	6-39

Chapter 7:	PRICES PAID AND PRICES CHARGED	
	7.1 Process Development Prices	7-1
	7.1.1 <i>Process Development Prices and Time Estimates: Mammalian</i>	7-1
	7.1.2 <i>Process Development Prices and Time Estimates: Microbial</i>	7-3
	7.1.3 <i>FTE Rates for Process Development</i>	7-5
	7.2 FTE Rates	7-7
	7.3 Contractors' Pricing Models	7-14
	7.4 Contractors' Short-Term versus Long-Term Rates	7-16
	7.4.1 <i>Contractors' Batch Pricing: Single versus Multiple Batches</i>	7-17
	7.4.2 <i>Contractors' Batch Pricing: Stainless Steel versus Single-Use</i>	7-20
	7.4.3 <i>Batch Pricing: Microbial Refolding</i>	7-21
	7.5 Pricing: Per-Batch, Per-Week, and Per-Gram	7-22
	7.5.1 <i>Per-Batch Pricing: Contractor versus User Averages</i>	7-23
	7.5.2 <i>Time-in-Facility Pricing: Contractor versus User Averages</i>	7-26
	7.5.3 <i>Price-Per-Gram: Contractor versus User Averages</i>	7-28
	7.6 Special Analysis: Price Per-Gram 2016 versus 2013	7-30
	7.7 Special Analysis: Price Per-Batch or Per-Week, Per-Liter	7-33
	7.8 Typical Charges for Additional Services	7-37
	7.8.1 <i>Typical Charges for Mammalian Cell Culture Services</i>	7-38
	7.8.2 <i>Typical Charges for Microbial Fermentation Services</i>	7-44

Biopharmaceutical Contract Manufacturing: Best Practices Pricing Study 2016

TABLE OF CONTENTS (continued)

Chapter 8:	IMPROVING CONTRACT AGREEMENTS AND FINAL OBSERVATIONS	
8.1	Contract Negotiations for Production	8-1
8.1.1	<i>Users' Perspective: Negotiation Challenges</i>	8-1
8.1.2	<i>Contractors' Perspective: Negotiation Challenges</i>	8-5
8.2	Users' Perspective: Preparing for Problems	8-8
8.2.1	<i>Users' Experience with Cancellation Fees for GMP Runs</i>	8-8
8.2.2	<i>Users' Cancellation Fees for Development/Non-GMP Batches</i>	8-11
8.2.3	<i>Users' Frequency of Change Orders</i>	8-14
8.3	Contractors' Perspectives: Preparing for Problems	8-19
8.3.1	<i>Contractors' Reservation Fees For GMP Runs</i>	8-19
8.3.2	<i>Contractors' Reservation Fees for Development/Non-GMP Batches</i>	8-22
8.3.3	<i>Contractors' Cancellation Fees for GMP Runs</i>	8-25
8.3.4	<i>Contractors' Cancellation Fees for Development/Non-GMP Batches</i>	8-26
8.3.5	<i>Flexibility in Rescheduling Manufacturing Campaigns</i>	8-28
8.3.6	<i>Users' Tolerance of CMO Rescheduling</i>	8-31
8.4	Final Observations	8-34
8.4.1	<i>Concerns Regarding Capital Expenditures or Supply Capability</i>	8-34
8.4.2	<i>Changes in Commercial Contract Terms Due to Capacity Concerns</i>	8-41
8.4.3	<i>Commoditization of Biopharmaceutical Manufacturing</i>	8-44
8.4.4	<i>Market Challenges: CMOs</i>	8-49
8.4.5	<i>Users' Perspective: Other Observations</i>	8-53
8.4.6	<i>Contractors' Perspective: Other Observations</i>	8-56

Biopharmaceutical Contract Manufacturing: Best Practices Pricing Study 2016

LIST OF TABLES

Chapter 1

1.3-1	Reasons for Changes in CMO Pricing in the Next Two Years	1-5
1.4-1	Important Factors in Decision-Making Process Besides Price	1-9
1.4-2	Reasons for Needing Technical Support from a CMO	1-11
1.4-3	Reasons for Needing/Not Needing Regulatory Support from a CMO	1-11
1.4-4	Circumstances for Using China CMO for Chinese Market	1-13
1.5-1	Contractors' Client Base by Segment	1-14
1.5-2	Strategies for Managing Development Risk: CMOs	1-18
1.6-1	Pricing Models Preferred by Users by Percentage	1-19
1.6-2	Pricing Models Preferred by Users by Product Phase	1-21
1.6-3	Services Users are Willing to Pay Premium for Speed	1-23
1.6-4	Payment of Premium for Speed or Earliest Available Capacity	1-24
1.6-5	Additional Areas Where Premium Might be Paid	1-25
1.7-1	Contractor Preferred Pricing Models by Project Phase	1-29
1.8-1	Users' Perspective: Challenges in Contract Negotiations	1-37
1.8-2	Contractors' Perspective: Challenges in Contract Negotiations	1-38
1.8-3	Comparison of Contractor and User Cancellation Fees for GMP Runs	1-40
1.8-4	Observations of Clients' Tolerance of CMO Rescheduling	1-41
1.8-5	Additional User Observations about Pricing and Contract Agreements	1-43
1.8-6	Additional Contractor Observations about Pricing and Contract Agreements	1-44

Chapter 2

2.2-1	Market Research Steps	2-2
2.5-1	Acronyms	2-4

Chapter 3

3.1-1	Titles of Respondents Listed Alphabetically	3-2
3.2-1	Reasons for Changes in CMO Pricing in the Next Two Years	3-10
3.2-2	Services Where Prices Have Changed the Most	3-15
3.2-3	Factors Affecting Manufacturing Costs: CMOs	3-17
3.3-1	Contractors' Target Gross Profit Margins	3-21

Chapter 4

4.2-1	Contract Manufacturers Used by Respondents	4-15
4.2-2	Contract Manufacturers Being Considered by Respondents	4-17
4.2-3	Reasons Why a New or Different CMO is Being Considered	4-18
4.3-1	Final Decision Maker for CMO Selection	4-27
4.3-2	Change in Decision Maker for CMO Selection as Project Progresses	4-29
4.3-3	Important Factors in Decision-Making Process Besides Price	4-35
4.3-4	Important Factors in Outsourcing Mammalian Cell-Line Development	4-39
4.3-5	Reasons for Needing Technical Support from a CMO	4-43
4.3-6	Reasons for Needing/Not Needing Regulatory Support from a CMO	4-44
4.3-7	Types of Business Arrangements in Co-Working with CMO	4-50
4.3-8	Concerns to be Addressed Before Proceeding	4-54

Biopharmaceutical Contract Manufacturing: Best Practices Pricing Study 2016

LIST OF TABLES (continued)

Chapter 4

4.4-1	Reasons for Importance of Geographic Location in CMO Selection	4-58
4.4-2	Reasons for Not Considering an Asia-Based CMO	4-63
4.4-3	Circumstances for Using China CMO for Chinese Market	4-67
4.5-1	Expression Systems Used by Respondents	4-72
4.5-2	Reasons for Use of Expression Systems	4-73
4.5-3	New Technologies Needed at CMOs	4-83

Chapter 5

5.1-1	CMOs' Additional Services Strategies	5-2
5.1-2	Strategies for Managing Development Risk: CMOs	5-12
5.2-1	Percentage of Clients: Fee-for-Service versus Partnership Contracts	5-15
5.2-2	Contractors' Client Base by Segment	5-18
5.3-1	Pass-Through Cost Payment Terms	5-27

Chapter 6

6.1-1	Pricing Models Preferred by Users by Percentage	6-3
6.1-2	Pricing Models Preferred by Users by Product Phase	6-5
6.1-3	Services Users are Willing to Pay Premium for Speed	6-7
6.1-4	Strategies for Managing Development Risk: Users	6-18
6.2-1	Payment of Premium for Speed or Earliest Capacity Availability	6-25
6.2-2	Additional Areas Where Premium Might be Paid	6-26
6.2-3	Attributes of Long-Term Agreements	6-37

Chapter 7

7.3-1	Contractors' Preferred Pricing Models by Project Phase	7-15
7.5-1	Average Number of Batches Per Project By Tank Size	7-22
7.5-2	Average Number of Weeks Per Project By Tank Size	7-23
7.5-3	Average Number of Grams Per Project By Tank Size	7-23
7.6-1	Number of Users' Products Included in the Analysis	7-30
7.8-1	Prices Paid or Charged for Additional Services: Mammalian Cell Culture	7-42
7.8-2	Prices Paid or Charged for Additional Services: Microbial Fermentation	7-47

Chapter 8

8.1-1	Users' Perspective: Challenges in Contract Negotiations	8-2
8.1-2	Contractors' Perspective: Challenges in Contract Negotiations	8-6
8.2-1	Types and Amounts of Cancellation Fees for Development Services or Non-GMP Batches	8-12
8.2-2	Users' Payment of Change Orders	8-16

Biopharmaceutical Contract Manufacturing: Best Practices Pricing Study 2016

LIST OF TABLES (continued)

Chapter 8

8.3-1	Reservation Fee Arrangements for Development Services or Non-GMP Batches	8-23
8.3-2	Comparison of Contractor and User Cancellation Fees	8-26
8.3-3	Cancellation Fees for Development Services or Non-GMP Batches	8-27
8.3-4	Rescheduling Offerings for Manufacturing Campaigns	8-29
8.3-5	Observations of Clients' Tolerance for CMO Rescheduling	8-32
8.4-1	Concerns Regarding Capital Expenditures or Supply Capabilities	8-36
8.4-2	Types of Changes in Commercial Contract Terms	8-42
8.4-3	Areas of Commoditization	8-45
8.4-4	Barriers to Commoditization	8-45
8.4-5	Future Market Challenges for Biopharmaceutical Contract Manufacturing	8-50
8.4-6	Additional User Observations about Pricing and Contract Agreements	8-54
8.4-7	Additional Contractor Observations about Pricing and Contract Agreements	8-56

Biopharmaceutical Contract Manufacturing: Best Practices Pricing Study 2016

LIST OF FIGURES

Chapter 1

1.2-A	Locations of Study Participants	1-3
1.3-A	Opinions Regarding Price Changes in the Past Two Years	1-4
1.3-B	Changes in CMO Pricing in the Next Two Years	1-5
1.4-A	Summary of Outsourcing Strategies	1-7
1.4-B	Rating of Importance of Price in Decision-Making Process	1-8
1.4-C	Importance of Price for Commercial Supply	1-8
1.4-D	Technical Support Expected from a CMO	1-10
1.4-E	Regulatory Support Expected from a CMO	1-10
1.4-F	Interest in Using China CMO for Chinese Market	1-12
1.5-A	Contractors' Client Base by Segment	1-14
1.5-B	Rating of Importance of Price in Clients' Decision-Making Process	1-15
1.5-C	Comparison of CMO and User Rating of Importance of Price in Decision-Making	1-16
1.5-D	Provisions for Inflation in Contracts	1-17
1.6-A	Pricing Models Preferred by Users	1-20
1.6-B	Willingness to Pay Premium for Speed or Earliest Capacity Availability	1-22
1.6-C	Distribution of Average Premium for Speed or Earliest Capacity Availability	1-22
1.6-D	Distribution of Expected Premium for Speed or Earliest Capacity Availability	1-25
1.6-E	Comparison of Premium for Speed or Earliest Capacity Availability	1-26
1.6-F	Contractors' Pricing Model for Development Services	1-27
1.7-A	Contractors: Primary Pricing Models	1-28
1.7-B	Contractor Preferred Pricing Models by Project Phase	1-29
1.7-C	Per-Batch Pricing: Average Prices Charged and Paid: Mammalian	1-31
1.7-D	Per-Batch Pricing: Average Prices Charged and Paid: Microbial	1-32
1.7-E	Time-in-Facility Pricing: Average Prices Charged and Paid: Mammalian	1-33
1.7-F	Time-in-Facility Pricing: Average Prices Charged and Paid: Microbial	1-34
1.7-G	Per-Gram Pricing: Fee Per Gram by Project Volumes: Mammalian	1-35
1.7-H	Per-Gram Pricing: Fee Per Gram by Project Volumes: Microbial	1-36
1.8-A	Contractors' Cancellation Fees for GMP Runs	1-39
1.8-B	Users' Tolerance of CMO Rescheduling	1-41

Chapter 2

2.4-A	Explanation of Box-and-Whiskers Plot	2-4
-------	--------------------------------------	-----

Chapter 3

3.1-A	Locations of Study Participants	3-2
3.1-B	Respondents with Biopharmaceutical Products on the Market	3-4
3.1-C	Respondents with Biopharmaceuticals in Clinical Trials	3-5
3.1-D	Number of Biopharmaceuticals in Clinical Trials	3-5
3.1-E	Product Produced in CMO Facility Licensed for Commercial Production	3-6
3.2-A	Opinions Regarding Price Changes in the Past Two Years	3-8
3.2-B	Changes in CMO Pricing in the Next Two Years	3-10
3.3-A	Contractors' Target Gross Profit Margins by Phase: 2016 and 2019	3-22

Biopharmaceutical Contract Manufacturing: Best Practices Pricing Study 2016

LIST OF FIGURES (continued)

Chapter 4

4.1-A	Outsource versus In-House Manufacturing	4-1
4.1-B	Manufacturing Budgets: Outsourced versus In-House	4-2
4.1-C	Percentage of Budget Spent on Outsourcing	4-3
4.1-D	Change in Proportion of Manufacturing Budget for Outsourced Production	4-4
4.1-E	Outsourcing Budgets: Process Development versus Manufacturing	4-5
4.1-F	Level of Outsource Spending for Process Development and Manufacturing	4-6
4.1-G	Change in Outsourcing Spending for Process Development and Manufacturing	4-7
4.1-H	Summary of Outsourcing Strategies	4-8
4.1-I	Future Changes in Outsourcing Strategy	4-12
4.2-A	Plan to Use New or Different CMO	4-17
4.3-A	Initial Discussions with Contractors	4-22
4.3-B	Number of CMOs that Users Seek Proposals From	4-25
4.3-C	Change in Decision Maker for CMO Selection as Project Progresses	4-29
4.3-D	Rating of Importance of Price in Decision-Making Process	4-34
4.3-E	Importance of Price for Commercial Supply	4-34
4.3-F	Technical Support Expected from a CMO	4-42
4.3-G	Regulatory Support Expected from a CMO	4-42
4.3-H	Interest in Co-Work Opportunities with CMO	4-49
4.3-I	Consideration of Low Base Price with Bonuses Tied to Target	4-53
4.4-A	Effect of Geographic Location on CMO Selection	4-57
4.4-B	Willingness to Use an Asia-Based CMO	4-62
4.4-C	Interest in Using China CMO for Chinese Market	4-67
4.5-A	Use of Expression Systems	4-71
4.5-B	Preferred Payment Model for Proprietary Expression Systems	4-77
4.5-C	Changing Product Portfolio	4-82
4.5-D	New Technologies Needed at CMO	4-82

Chapter 5

5.1-A	Phase-Based Business Focus	5-1
5.1-B	Rating of Importance of Price in Clients' Decision-Making Process	5-5
5.1-C	Comparison of CMO and User Rating of Importance of Price in Decision-Making	5-6
5.1-D	Provisions for Inflation in Contracts	5-9
5.2-A	Fee-for-Service versus Partnership Contracts	5-16
5.2-B	Percent of Clients Located in Same Country as Contractor's Facility	5-17
5.2-C	Contractors' Client Base by Segment	5-18
5.3-A	Treatment and Charging of Engineering Runs	5-19
5.3-B	Average Number of Runs in a Campaign	5-21
5.3-C	Engineering Runs Included in Campaign	5-22
5.3-D	Provisions for Raw and Consumable Materials	5-24
5.3-E	Average Markup Charge for Pass-Through Costs	5-27
5.3-F	Charging for Product Support/Project Management	5-30
5.3-G	Implementation of Electronic Documentation	5-32

Biopharmaceutical Contract Manufacturing: Best Practices Pricing Study 2016

LIST OF FIGURES (continued)

Chapter 6

6.1-A	Services Types Expected to <u>Be Included</u> in Batch Pricing	6-2
6.1-B	Services Types Expected to <u>Not Be Included</u> in Batch Pricing	6-2
6.1-C	Pricing Models Preferred by Users	6-4
6.1-D	Willingness to Pay Premium for Speed or Earliest Capacity Availability	6-6
6.1-E	Distribution of Average Premium for Speed or Earliest Capacity Availability	6-6
6.1-F	Pricing Distribution for Mammalian Cell-Line Development	6-11
6.1-G	Time Frame Distribution for Mammalian Cell-Line Development	6-12
6.1-H	Clients' CMO Charging Markups for Purchased Materials	6-14
6.1-I	Distribution of Users' Material Markups Charged by Their CMO	6-15
6.1-J	Comparison of CMO Markups Charged for Purchased Materials	6-15
6.1-K	Management of Development Risk Comparison: Users versus CMOs	6-19
6.2-A	Distribution of Expected Premium for Speed or Earliest Capacity Availability	6-26
6.2-B	Comparison of Premium for Speed or Earliest Capacity Availability	6-27
6.2-C	Contractors' Pricing Model for Development Services	6-30
6.2-D	Charging for Pre-Production Services	6-32
6.2-E	Provide IND Submission Service	6-34
6.2-F	How IND Services are Charged	6-34
6.2-G	Long-Term Contracts with Clients	6-37
6.2-H	Price Reduction Provisions from Process Improvements	6-40

Chapter 7

7.1-A	Estimates of Process Development Cost: Mammalian Process	7-2
7.1-B	Estimates of Process Development Hours: Mammalian Process	7-3
7.1-C	Estimates of Process Development Cost: Microbial Process	7-4
7.1-D	Estimates of Process Development Hours: Microbial Process	7-5
7.1-E	Annual FTE Rates for Process Development	7-6
7.1-F	FTE Rates for Process Development: Users' Expectations versus Experience	7-7
7.2-A	Annual FTE Rates for Manufacturing Staff	7-8
7.2-B	Annual FTE Rates for QC Staff	7-8
7.2-C	Annual FTE Rates for Project Management Staff	7-9
7.2-D	Annual FTE Rates for Regulatory Support Staff	7-9
7.2-E	Annual FTE Rates for Analytic Development Staff	7-10
7.2-F	FTE Rates for Management Staff: Users' Expectations versus Experience	7-11
7.2-G	FTE Rates for QC Staff: Users' Expectations versus Experience	7-12
7.2-H	FTE Rates for Project Management: Users' Expectations versus Experience	7-12
7.2-I	FTE Rates for Regulatory Support: Users' Expectations versus Experience	7-13
7.2-J	FTE Rates for Analytic Development: Users' Expectations versus Experience	7-13
7.3-A	Contractors: Primary Pricing Models	7-14
7.3-B	Contractors' Preferred Pricing Models by Project Phase	7-16
7.4-A	Batch Pricing: Average CMO Rates Per Batch or Run: Mammalian Single Batch versus Multiple Batches	7-18
7.4-B	Batch Pricing: Average CMO Rates Per Batch or Run: Microbial Single Batch versus Multiple Batches	7-19
7.4-C	Batch Pricing: Average CMO Rates Per Batch: Mammalian Stainless Steel versus Single-Use	7-20

Biopharmaceutical Contract Manufacturing: Best Practices Pricing Study 2016

LIST OF FIGURES (continued)

Chapter 7

7.4-D	Batch Pricing: Average Rates Per Batch: Microbial No Refolding versus Refolding	7-21
7.5-A	Per-Batch Pricing: Average Prices Charged and Paid: Mammalian	7-24
7.5-B	Per-Batch Pricing: Average Prices Charged and Paid: Microbial	7-25
7.5-C	Time-in-Facility Pricing: Average Prices Charged and Paid: Mammalian	7-26
7.5-D	Time-in-Facility Pricing: Average Prices Charged and Paid: Microbial	7-27
7.5-E	Per-Gram Pricing: Average Prices Charged and Paid: Mammalian	7-28
7.5-F	Per-Gram Pricing: Average Prices Charged and Paid: Microbial	7-29
7.6-A	Per-Gram Pricing: Fee per Gram by Project Volumes: Mammalian	7-32
7.6-B	Per-Gram Pricing: Fee per Gram by Project Volumes: Microbial	7-33
7.7-A	Per-Batch Pricing: Fee per Batch per Liter by Tank Size	7-34
7.7-B	Time-in-Facility Pricing: Fee per Batch per Liter by Tank Size	7-35
7.7-C	Explanation of Box-and-Whiskers Plot	7-36
7.7-D	Box-and-Whiskers Plot: Per-Batch Pricing: Mammalian Cell Culture	7-36
7.7-E	Box-and-Whiskers Plot: Per-Batch Pricing: Microbial Fermentation	7-37
7.8-A	Average Price Paid by Users for Additional Services: Mammalian-1	7-38
7.8-B	Average Price Paid by Users for Additional Services: Mammalian-2	7-39
7.8-C	Average Price Paid by Users for Additional Services: Mammalian-3	7-39
7.8-D	Average Price Paid by Users for Additional Services: Mammalian-4	7-40
7.8-E	Average Price Charged by CMOs for Additional Services: Mammalian-1	7-40
7.8-F	Average Price Charged by CMOs for Additional Services: Mammalian-2	7-41
7.8-G	Average Price Charged by CMOs for Additional Services: Mammalian-3	7-41
7.8-H	Average Price Paid by Users for Additional Services: Microbial-1	7-44
7.8-I	Average Price Paid by Users for Additional Services: Microbial-2	7-45
7.8-J	Average Price Paid by Users for Additional Services: Microbial-3	7-45
7.8-K	Average Price Charged by CMOs for Additional Services: Microbial-1	7-46
7.8-L	Average Price Charged by CMOs for Additional Services: Microbial-2	7-46
7.8-L	Average Price Charged by CMOs for Additional Services: Microbial-3	7-47

Chapter 8

8.2-A	Cancellation Fees Paid by Users for GMP Runs	8-9
8.2-B	Cancellation Fees for Development Services or Non-GMP Batches	8-11
8.2-C	Users' Change Orders	8-15
8.2-D	Users' Frequency of Change Orders	8-15
8.3-A	Distribution of Average Reservation Fees for GMP Runs Charged by CMOs	8-20
8.3-B	Charging of Reservation Fees for GMP Runs	8-20
8.3-C	Time Slot Guarantee and When Reservation Fee is Paid	8-21
8.3-D	Reservation Fee Differences Between GMP Runs and Development Services	8-23
8.3-E	Contractors' Cancellation Fees for GMP Runs	8-25
8.3-F	Charging of Cancellation Fees for Development Services or Non-GMP Batches	8-27
8.3-G	Users' Tolerance of CMO Rescheduling	8-31
8.4-A	Concerns Regarding Capital Expenditures or Supply Capability	8-35
8.4-B	Change in Commercial Contract Terms	8-42
8.4-C	Commoditization in the Biopharmaceutical Manufacturing Industry	8-44
